Epidemiology and outcomes of early-onset AKI in COVID-19-related ARDS in comparison with non-COVID-19-related ARDS: insights from two prospective global cohort studies.
28-day mortality
90-day mortality
ARDS
Acute kidney injury
COVID-19
Cohort study
Outcome
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
05 01 2023
05 01 2023
Historique:
received:
13
09
2022
accepted:
25
12
2022
entrez:
5
1
2023
pubmed:
6
1
2023
medline:
10
1
2023
Statut:
epublish
Résumé
Acute kidney injury (AKI) is a frequent and severe complication of both COVID-19-related acute respiratory distress syndrome (ARDS) and non-COVID-19-related ARDS. The COVID-19 Critical Care Consortium (CCCC) has generated a global data set on the demographics, management and outcomes of critically ill COVID-19 patients. The LUNG-SAFE study was an international prospective cohort study of patients with severe respiratory failure, including ARDS, which pre-dated the pandemic. The incidence, demographic profile, management and outcomes of early AKI in patients undergoing invasive mechanical ventilation for COVID-19-related ARDS were described and compared with AKI in a non-COVID-19-related ARDS cohort. Of 18,964 patients in the CCCC data set, 1699 patients with COVID-19-related ARDS required invasive ventilation and had relevant outcome data. Of these, 110 (6.5%) had stage 1, 94 (5.5%) had stage 2, 151 (8.9%) had stage 3 AKI, while 1214 (79.1%) had no AKI within 48 h of initiating invasive mechanical ventilation. Patients developing AKI were older and more likely to have hypertension or chronic cardiac disease. There were geo-economic differences in the incidence of AKI, with lower incidence of stage 3 AKI in European high-income countries and a higher incidence in patients from middle-income countries. Both 28-day and 90-day mortality risk was increased for patients with stage 2 (HR 2.00, p < 0.001) and stage 3 AKI (HR 1.95, p < 0.001). Compared to non-COVID-19 ARDS, the incidence of shock was reduced with lower cardiovascular SOFA score across all patient groups, while hospital mortality was worse in all groups [no AKI (30 vs 50%), Stage 1 (38 vs 58%), Stage 2 (56 vs 74%), and Stage 3 (52 vs 72%), p < 0.001]. The time profile of onset of AKI also differed, with 56% of all AKI occurring in the first 48 h in patients with COVID-19 ARDS compared to 89% in the non-COVID-19 ARDS population. AKI is a common and serious complication of COVID-19, with a high mortality rate, which differs by geo-economic location. Important differences exist in the profile of AKI in COVID-19 versus non-COVID-19 ARDS in terms of their haemodynamic profile, time of onset and clinical outcomes.
Sections du résumé
BACKGROUND
Acute kidney injury (AKI) is a frequent and severe complication of both COVID-19-related acute respiratory distress syndrome (ARDS) and non-COVID-19-related ARDS. The COVID-19 Critical Care Consortium (CCCC) has generated a global data set on the demographics, management and outcomes of critically ill COVID-19 patients. The LUNG-SAFE study was an international prospective cohort study of patients with severe respiratory failure, including ARDS, which pre-dated the pandemic.
METHODS
The incidence, demographic profile, management and outcomes of early AKI in patients undergoing invasive mechanical ventilation for COVID-19-related ARDS were described and compared with AKI in a non-COVID-19-related ARDS cohort.
RESULTS
Of 18,964 patients in the CCCC data set, 1699 patients with COVID-19-related ARDS required invasive ventilation and had relevant outcome data. Of these, 110 (6.5%) had stage 1, 94 (5.5%) had stage 2, 151 (8.9%) had stage 3 AKI, while 1214 (79.1%) had no AKI within 48 h of initiating invasive mechanical ventilation. Patients developing AKI were older and more likely to have hypertension or chronic cardiac disease. There were geo-economic differences in the incidence of AKI, with lower incidence of stage 3 AKI in European high-income countries and a higher incidence in patients from middle-income countries. Both 28-day and 90-day mortality risk was increased for patients with stage 2 (HR 2.00, p < 0.001) and stage 3 AKI (HR 1.95, p < 0.001). Compared to non-COVID-19 ARDS, the incidence of shock was reduced with lower cardiovascular SOFA score across all patient groups, while hospital mortality was worse in all groups [no AKI (30 vs 50%), Stage 1 (38 vs 58%), Stage 2 (56 vs 74%), and Stage 3 (52 vs 72%), p < 0.001]. The time profile of onset of AKI also differed, with 56% of all AKI occurring in the first 48 h in patients with COVID-19 ARDS compared to 89% in the non-COVID-19 ARDS population.
CONCLUSION
AKI is a common and serious complication of COVID-19, with a high mortality rate, which differs by geo-economic location. Important differences exist in the profile of AKI in COVID-19 versus non-COVID-19 ARDS in terms of their haemodynamic profile, time of onset and clinical outcomes.
Identifiants
pubmed: 36604753
doi: 10.1186/s13054-022-04294-5
pii: 10.1186/s13054-022-04294-5
pmc: PMC9814373
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3Subventions
Organisme : Marie Skłodowska-Curie grant
ID : 754550
Organisme : "la Caixa" Foundation
ID : 100010434
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Ann Intensive Care. 2018 Feb 23;8(1):30
pubmed: 29473104
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Am J Respir Crit Care Med. 2020 Nov 1;202(9):1299-1301
pubmed: 32866028
Crit Care Med. 2021 Jan 1;49(1):102-111
pubmed: 33116052
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Intensive Care Med. 2020 Apr;46(4):654-672
pubmed: 31820034
Kidney Med. 2021 Jan-Feb;3(1):83-98.e1
pubmed: 33319190
Lancet Respir Med. 2021 Sep;9(9):989-998
pubmed: 34224674
BMJ Open. 2020 Dec 2;10(12):e041417
pubmed: 33268426
JAMA. 2003 Apr 23-30;289(16):2104-12
pubmed: 12709468
Sci Data. 2022 Jul 30;9(1):454
pubmed: 35908040
Crit Care. 2022 Jul 25;26(1):225
pubmed: 35879765
Intensive Care Med. 2022 Nov;48(11):1632-1634
pubmed: 35974191
JAMA. 2016 Feb 23;315(8):788-800
pubmed: 26903337
N Engl J Med. 2021 Nov 4;385(19):1737-1749
pubmed: 34554658
Medicines (Basel). 2021 Jan 07;8(1):
pubmed: 33430296
Kidney Int Rep. 2021 Jan 01;6(3):645-656
pubmed: 33732979
Nat Rev Nephrol. 2021 Nov;17(11):751-764
pubmed: 34226718
Nat Rev Nephrol. 2020 Dec;16(12):747-764
pubmed: 33060844
Intensive Care Med. 2015 Aug;41(8):1411-23
pubmed: 26162677
J Am Soc Nephrol. 2020 Jul;31(7):1380-1383
pubmed: 32366514
J Am Soc Nephrol. 2021 Jan;32(1):161-176
pubmed: 33067383
Intensive Care Med. 2020 May;46(5):1072-1073
pubmed: 32095847
Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1347-53
pubmed: 24875195
Lancet Respir Med. 2020 Jul;8(7):738-742
pubmed: 32416769
Intensive Care Med. 2020 Jun;46(6):1114-1116
pubmed: 32236644
Nephrol Dial Transplant. 2022 Jan 25;37(2):271-284
pubmed: 34661677
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Kidney Int. 2020 Jul;98(1):219-227
pubmed: 32327202
Ann Intensive Care. 2022 May 21;12(1):42
pubmed: 35596885
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
J Am Soc Nephrol. 2020 Sep;31(9):2145-2157
pubmed: 32669322
Crit Care. 2013 May 27;17(3):R98
pubmed: 23710662
Clin J Am Soc Nephrol. 2021 Nov;16(11):1755-1765
pubmed: 34127485
Kidney Int. 2020 Jul;98(1):209-218
pubmed: 32416116
Crit Care Med. 2019 Sep;47(9):1216-1225
pubmed: 31162201
Front Med (Lausanne). 2021 May 28;8:647023
pubmed: 34124089